Prestige Biologics Co., Ltd. (KOSDAQ:334970)
1,687.00
-13.00 (-0.76%)
At close: Sep 9, 2026
Prestige Biologics Market Cap
Prestige Biologics has a market cap or net worth of 131.17 billion as of September 9, 2026. Its market cap has decreased by -53.14% in one year.
Market Cap
131.17B
Enterprise Value
215.60B
Revenue
18.03B
Ranking
n/a
PE Ratio
n/a
Stock Price
1,687.00
ChartMarket Cap Chart
Since March 11, 2021, Prestige Biologics's market cap has decreased from 613.27B to 131.17B, a decrease of -78.61%. That is a compound annual growth rate of -24.45%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 9, 2026 | 131.17B | -44.42% |
| Dec 30, 2025 | 235.98B | -40.12% |
| Dec 30, 2024 | 394.06B | 46.25% |
| Dec 28, 2023 | 269.45B | 46.01% |
| Dec 29, 2022 | 184.55B | -59.28% |
| Dec 30, 2021 | 453.18B | -26.10% |
| Mar 11, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Kanaph Therapeutics | 190.60B |
| Genome & Company | 180.17B |
| NIBEC | 172.22B |
| Bio Solution | 165.15B |
| Ensol Biosciences | 146.64B |
| TiumBio | 141.93B |
| ISU Abxis | 138.43B |
| Y-Biologics | 138.15B |